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Abstract

Introduction

This paper reviews the clinical and experimental
findings on the effects of sodium fluoride (NaF) on
human and animal bone. NaF has been shown to cause
a significant increase in axial skeletal bone mass.
However, there is concern that the new bone may not
provide the desired increase in bone strength. Yet, NaF
remains the most commonly used agent capable of stimulating bone formation in most patients (30% non-responders).. But whether NaF reduces vertebral fracture
rate (VFR) remains controversial. For a given treatment
duration, the effect of F on bone quality appears to depend on dose: there is a marked detrimental effect on
bone strength at high dose but there tends to be a beneficial effect at low dose. This biphasic NaF effect on
bone strength has also been observed in fluoridated rat
femurs. Unlike a study on young female rats which
shows a linear dependence of cancellous bone volume
(Cn-BV /TV) on NaF dose, a short-term study on young
male rats, together with studies on chicks and dogs show
biphasic NaF effects. Biphasic character is also observed in the effect of NaF on the packing of canine cortical bone mineral. When taken together, the animal
models that show biphasic NaF effects seem to suggest
that NaF at low dose improves Cn-BV/TV and bone
strength and at high dose undermines them. These findings are in agreement with the clinical observations that
high NaF dose does not help reduce VFR but low dose
seems to help.

In senile osteoporosis and in postmenopausal osteoporosis, the amount of bone resorbed is not fully compensated by the amount of bone formed. This dynamic
imbalance has to be corrected if we want to treat these
types of osteoporosis. The corrective measures taken at
present are mainly experimental and involve either stimulating bone formation or inhibiting bone resorption. In
normal or osteoporotic bone, the cellular processes for
bone formation and bone resorption are coupled (Parfitt,
1988). As a consequence, antiresorptive regimens including estrogen, calcitonin, and bisphosphonates, will
prevent further bone loss, but will not build up bone
mass after one or two years. The same coupling effect
also limits the formation-stimulating regimens from
building up bone mass beyond the time when a new dynamic remodeling equilibrium is achieved (Ke et al.,
1992). However, in practice, formation-stimulating regimens including sodium fluoride (NaF), parathyroid hormone {PTH), and various growth factors, can build up
bone mass more effectively, and for a longer period of
time than antiresorptive regimens (Riggs, 1990). In
fact, when NaF (Parfitt, 1988) or PTH (Hock et al.,
1989) or prostaglandin~ (Jee et al., 1994) is the stimulating agent, there seems to be an "unbalanced coupling"
in favour of bone formation, with some new bone formation taking place on inactive bone surface without a
preceding resorption phase (modeling in the formation
mode).
Oral NaF treatment, at 1 mg/kg/d, for postmenopausal osteoporosis has produced mixed results. It has
been shown to cause a significant increase in axial skeletal bone mass (Briancon and Meunier, 1981; Harrison et
al., 1981; Lane et al., 1984; Eriksen et al., 1985; Riggs
et al., 1990; Kleerekoper et al., 1991). However, there
is concern that when NaF is given at approximately 1
mg/kg/d, the new bone may not provide the desired increase in bone strength as the new bone may be woven
in nature and hyperosteoidosis may be present. At 1-1.4
mg/kg/d, a long-term study has shown that hyperosteoidosis after 7 years is not as severe as after 3 years
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mentioned above, at the therapeutic dose of 1 mglkg/d,
NaF stimulates bone formation. New bone forms on the
surface of existing trabeculae but remodelling of the
thickened trabeculae is lacking (Aaron et al., 1992). In
vitro experiments also show that the fluoridated bone is
more resistant to osteoclastic resorption (Okuda et al.,
1990) and acid dissolution (Grynpas and Cheng, 1988).
Small-angle X-ray scattering of fluoridated bone shows
the presence of new bone laid down on the surface of
preexisting trabeculae (Fratzl et al., 1994). Its mineral
structure is characterized by the presence of additional
large crystals, presumably located outside the collagen
fibrils. These abnormal large crystals contribute to increase the bone mineral density without significantly improving the bone strength (Fratzl et al., 1994). Another
backscattered electron imaging study also shows that
degree of mineralization increases with NaF treatment
(Grynpas et al., 1994). Treatment duration is another
parameter in the NaF effect on bone strength. At the
therapeutic dose, NaF begins to show an adverse effect
on bone strength after one year, and the effect is more
serious after five years (Sogaard et al., 1994).
In addition to treatment duration, the effect ofF on
bone quality appears to depend also on dose: there is a
marked detrimental effect on bone strength at high dose
but there tends to be a beneficial effect at low dose
(Lees and Hanson, 1992). This biphasic NaF effect on
bone strength bas also been observed in fluoridated rat
femurs (Turner et al. , 1992). Clinically , it has also
been shown that the effect of NaF on VFR is biphasic:
VFR decreases when the effective NaF dose is low and
then increases when the dose is high (Riggs et al.,
1994). The biphasic character of NaF effects is observed also in animal studies and will be discussed again
in later sections.

(Lundy et al., 1989). At lower dose, it has been reported that lamellar bone without hyperosteoidosis is formed
(Mamelle et al., 1988). Another study reports that
defective mineralization is significantly correlated to
high bone fluoride content (Boivin et al., 1993) and
bone fluoride content is affected by several factors including the dose, the bio~vailability of the compound
used and the duration of treatment (Boivin et al., 1988).
Also, it has been suggested that NaF increases cancellous bone mineral density but decreases that of cortical
bone, causing the non-vertebral fracture rate of patients
to increase (Riggs et al., 19~0; Schnitzler et al., 1990b).
On the other hand, an intermittent treatment with slowrelease NaF (50 mg/day; four 3-month cycles in 20
months), together with continuous vitamin D and calcium therapy, produces new bone with normal material
quality (Pak et al., 1989; 1994; Zerwekh et al., 1992).
The benefit-to-risk ratio depends on the cumulative dose.
A treatment period of two years with low daily dose (50
mg in enteric-coated tablets) with calcium supplement is
considered safe (Meunier and Boivin, 1993).
To date, NaF remains . the most commonly used
agent capable of stimulating bone formation in most patients. However, approximately 30% of patients are
non-responders (Hodsman and Drost, 1989). It is the
only agent that is effective in reducing vertebral fracture
rate (VFR) in patients with the vertebral crush fracture
syndrome (Heaney et al., 1989). But whether NaF reduces vertebral fracture rate remains highly controversial. Until such time that NaF can be replaced by a
more effective drug, perhaps by antiresorptive agents
such as bisphosphonates (Storm et al., 1990; Watts et
al., 1990; Reid et al., 1994; Thiebaud et al., 1994), or
by another anabolic agent such as PTH (Reeve et al.,
1980; 1991), further research on the dosage, drug preparation and duration of treatment should be continued.
This paper attempts to review the clinical and experimental fmdings on the effects of NaF on human and animal bone so as to shed light on the use of NaF to treat
osteoporosis in humans.

Effects of NaF on bone histomorphometry
The architecture of a bone type is a major determining factor for F effect because, in addition to other pathophysiological factors including the rate of remodeling
activity, the bone surface area per unit volume directly
controls the fluoridation process. As a consequence,
NaF is well known to affect cortical and cancellous
bones differently (Cheng and Bader, 1990a; 1992; Riggs
et al., 1990; Zerwekh et al., 1992). In a canine study,
it has been shown that the cancellous F% and F /Ca increase significantly with NaF dose, whereas the cortical
F% and F/Ca do not (Cheng and Bader, 1990a; 1992).

Effects of NaF on Bone
Effects of NaF on bone quality
Long-term NaF therapy affects bone in several
ways. The biology and chemistry of the bone are both
affected but to a different extent. What is observed clinically is the combined result of both effects in the form
of modified bone quantity and quality. The bone fluoride content varies according to exposure time and dose.
While the iliac biopsies of normal subjects contain 0.05
to 0.08% by weight ofF, those of NaF treated patients
contain 0.24 to 0.67% and those from patients with fluorosis contain 0.56 to 1.33% (Boivin et al. , 1988). As

Effects of NaF on cancellous bone
Extensive work has been done on the NaF effect on
human cancellous bone. Some deal with patients suffering skeletal fluorosis (Boivin et al. , 1989). Many deal
with the effects of therapeutic NaF dose (about 1
mg/kg/d) . However, most of these studies employed
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on these static morphometric observations, one can
safely say that NaF at therapeutic dose stimulates bone
formation but also promotes bone resorption, albeit to a
lesser extent. In most of the studies listed in Table 1,
dynamic histomorphometric parameters were either not
measured or non-significantly changed. From the thirteen entries listed in Table 1, there are only three significant changes, an elevated mineral apposition rate in
one case and two reduced adjusted appqsition rates in
two other cases. Hence, no conclusions can be drawn
with certainty from the dynamic data.

other drugs such as calcium, vitamin D and phosphorus
in addition to NaF (Briancon and Meunier, 1981; Vigorita and Suda, 1983; Eriksen et al., 1985). So, it would
be difficult to isolate the effect of NaF alone from the
combined results. However, there are several animal
studies involving NaF alone, and the animals employed
include: pigs (Mosekilde et al., 1987), sheep (Chavassieux et al., 1991a; 1991b), dogs (Snow and Anderson,
1986; Cheng and Bader, 1992), rats (Turner et al.,
1989; Cheng and Bader, 1990b; Modrowski et al.,
1992; Cheng et al., 1994), mice (Marie and Hott, 1986)
and chicks (Lundy et al., 1986). For a complete list of
animal models and protocols in studies on fluoride on
bone, please see the review by Chavassieux (1990).
Table 1 compares some static and dynamic histomorphometric results for both humans and animals receiving
non-fluorotic NaF doses. Again, one cannot compare
human studies and animal studies directly as the former
usually employ other drugs as well as NaF and the latter
employ a wide range of NaF doses . In particular, rats
are usually given NaF doses much higher than human
therapeutic dose. Other factors that differ humans from
animals are diet, fluoride metabolism and bone remodeling activity.
Table 1 shows that in all human studies and most
animal studies NaF significantly increases cancellous
bone volume (Cn-BV/TV). In fact, there are a few
human studies which did not report a significant increase
(Schnitzler et al., l990a; Vesterby et al., 1991). However, whether or not the increase in vertebral cancellous
bone volume will protect the patients from new spinal
fractures is still controversial. Conflicting results have
been reported. A Mayo Clinic report suggests that the
increased Cn-BV /TV does not help reduce spinal fracture rate (Riggs et al., 1990). But there are other reports which find a reduced spinal fracture rate associated
with the increased Cn-BV /TV (Farley et al., 1990;
Meunier, 1990). Table 1 also shows that, in most cases,
NaF increases the cancellous fractional osteoid volume
(Cn-OV /BV) and osteoid surface (Cn-OS/BS). Only in
two cases, BV /TV was significantly decreased: one involved 12-month-old rats treated with high dose of NaF
(12 mg/kg/d) (Cheng et al., 1994) and the other involved young rats with an even higher dose (equivalent
to NaF at 55 mg/kg/d) (Turner et al., 1989). These results suggest that high NaF dose is toxic to bone. Also,
only in two studies was OS/BS reported to decrease significantly. It should be noted that one of these two studies involved dogs on a relatively low dose (0. 7 mg/kg/d)
for only 6 months (Snow and Anderson, 1986) and the
other involved rats on hjgh dose (8 mg/kg/d) for 3
months (Cheng and Bader, 1990b). In half of the cases,
NaF also stimulates cancellous bone resorption as measured by the fractional erosion surface (ES/BS) . Based

Effects of NaF on cortical bone
Little is known about the NaF effect on human cortical bone. One study examined transiliac bone biopsies
from 10 postmenopausal osteoporotic patients after 6
months and again after 5 years of NaF treatment. The
treatment had no effect on the cortical bone thickness
but increased the porosity by 50-75% (p < 0.05).
Also, after 5 years, the treatment increased the fraction
of osteons undergoing remodeling, showing some degree
of mineralization defect and lengthened remodeling
cycles (Kragstrup et al., 1989a). In another study of
transiliac biopsies from 29 patients suffering from skeletal fluorosis, both cortical thickness and porosity showed
significant increases (38% and 120%, respectively)
(Boivin et al., 1989). Non-vertebral fractures, including
periarticular, femoral neck and long-bone shaft, have
been found to be increased by NaF treatment in some
studies (Gutteridge et al., 1984; Hedlund and Gallagher,
1989; Riggs et al., 1990; Schnitzler et a/., 1990b).
Non-vertebral fractures usually happen later than vertebral fractures (Schnitzler et al., 1990b). However,
other studies have not confirmed their fmdings (Riggs et
al., 1987; Mamelle et al., 1988). In any case, there is
evidence that cortical bone rnineral density may decrease
with NaF treatment after two years of treatment
(Hodsman and Drost, 1989).
Not much more is known about the effects of NaF
on animal cortical bone. F -induced increases in femoral
cortical bone porosity (73 %, p < 0. 05) were observed
in pigs fed 2 mg/kg/d F for 6 months. Increased osteoid
density and fluorochrome label density, and reduced osteon radius, osteon wall thickness and canal radius were
also observed (Kragstrup et al. , 1989b). Sirnilar findings were observed in the ribs of ovariectomized beagle
dams fed 0. 7 mglkg/d NaF for 6 months, except that
there was a signjficant decrease in cortical bone porosity
(Snow and Anderson, 1985).

Dose dependence of NaF effects on bone
The therapeutic dose of NaF for continuous treatment of osteoporosis is approximately 1 mg/kg/d. This
dose is approximately 10-12 times larger than the equivalent dose of drinking water containing 1 mg/1 of NaF.
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Table 1. Effects of non-fluorotic NaF dose on static and dynamic histomorphometric results from cancellous bone.
Briancon
and Meunier
(1981)

Vigorita
and Suda
(1983)

Eriksen
et al.
(1985)

Lundy
et al.
(1989)

Chavassieux
et al.
(199la)

Chavassieux
et al.
(199lb)

Snow and
Anderson
(1986)

Animal

Human

Human

Human

Human

Sheep

Sheep

Dog

Dose mg/kg/d

1

1

1

0.6-1.4

1

3.5

0.7

Other drugs

Ca, vitD

Ca, vitD

Ca, P, vitD

Ca

Age

65 years

6 years

4 months

4years

Duration

24 months

18-24 months

60 months

50 months
(from 1st. bx)

45 days

120 days

6 months

Target

iliac

iliac

iliac

iliac

iliac

iliac

lumbar

BY/TV

t

t

t

t

ns

ns

ns

OV/BV

t

t

ns

ns

t

OS/BS

t

t

t

ns

t

t

'

ES/BS

ns

t

t

t

ns

66 years

Static parameters
(compared to 1st. bx)

Tb.Th
O.Th

ns

't

t

ns

t

ns

t

t

ns

ns

ns

ns

ns

t

Dynamic parameters
MAR

ns

Aj.AR

ns

ns

Notes: t = significant increase; ' = significant decrease; ns = not significant. BV = bone volume; TV = tissue
volume; OV = osteoid volume; BS = bone surface; OS = osteoid surface; ES = eroded surface; Tb. Th = trabecular
thickness; O.Th = osteoid thickness; MAR = mineral apposition rate; Aj.AR = adjusted apposition rate.

Recent studies on the effect of fluoridated water on bone
show that such low NaF dose has little or no effect on
the prevalence of fractures (Kroger et al., 1994; Cauley
et al. , 1995). At the therapeutic dose, there are side effects in some patients such as nausea, vomiting and osteoarticular pain (Briancon and Meunier, 1981; Riggs et
al., 1982). Also, as already mentioned above, non-vertebral fractures have been found to be more frequent in
some studies. It is believed that these adverse side effects are dose related (Meunier, 1990). In fact, at high

dose, F is well known for its toxicity (Roholm, 1937).
The pharmacology of high dose F-toxicity has been well
studied (Caruso et al., 1970). Its toxicity affects many
cellular functions in many organs including bone,
kidney, heart, liver, gut and others. It promotes some
but inhibits many other enzymatic processes. In addition
to its bio-organic toxic effects, its bio-inorganic effects
on bone and teeth mineralization and demineralization
could become excessive and pathologic. It is therefore
highly desirable to have NaF dose as low as possible.
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Table 1 (continued).
Cheng ·
et al.
(1994)

Cheng
and Bader
(1990a, 1992)

Mosekilde
et al.
(1987)

Turner
et al.
(1989)

Cheng
and Bader
(1990b)

Modrowski
et al.
(1992)

Marie
and Hott
(1986)

Dog

Pig

Rat

Rat

Rat

Rat

Mouse

Animal

1

4.4

17 55

8

1

12

0.8

Dose mg/kg/d
Other drugs

6 years

8 months

?5 weeks

6 weeks

3 months

1 year

21 days

Age

9 months

6 months

21 days

3 months

1-6 months

4 months

1 month

Duration

femur

lumbar

tibia

femur

tibia

femur

cauda

Target
Static parameters

t

t

t

t

t

~

t

t

~

t

BY/TV
OV/BV

OS

OS

t

OS

~

t

ns

ns

ns

ES/BS

~

OS

OS

OS

Tb.Th

OS

ns

OS

OS

t

OS

t

t

OS/BS

O.Th

Dynamic parameters

t

ns

OS

MAR
Aj.AR

OS

Cn-OS/BS was observed when 14-day-old chicks were
fed NaF solutions (0-8.4 mM) for 14 days, with OS/BS
first increasing with NaF dose peaking at 5 mM and
then decreasing with higher NaF doses (Lundy et al. ,
1986).

However, the dose dependence ofF effects on bone
has not been fully investigated. For humans, there is
only one dose-response curve published, showing percent change in bone mass per year as a function of NaF
dose (0 to 80 mg/day) (K.leerekoper and Balena, 1991).
At 80 mg/day, the effect of NaF begins to plateau.
Table 1 shows that in rats high NaF dose does decrease
Co-BY /TV (Turner et al. , 1989; Cheng et al., 1994).
Perhaps for humans, it will take a dose > 80 mg/day to
show adverse effects on bone mass.
There are only six animal studies reported so far
that studied the dose dependence of NaF.

Short-tenn biphasic F effect on young male rat
bone: In the second study, young male rats (140 g)
were fed solutions containing 2.0 mM or 4.5 mM F ad
libitum for 21 days. Fluoride intake was 56 or 183
~tmol/day (equivalent to 17 or 55 mg/kg/d NaF). Tibial
metaphyseal Cn-BV /TV was significantly increased at
2.0 mM F , but was significantly decreased at 4.5 mM.
With these two doses and the short treatment duration,
osteoblastic and osteoclastic surfaces were not significantly affected (Turner et al., 1989).

Biphasic NaF effect on chick bone: Chicks were
employed in the first study. A biphasic NaF effect on
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Figures 1 and 2. Analysis of canine proximal femoral cancellous bone volume (Fig. 1 at left) and cancellous mineral
apposition rate (Fig. 2 at right) according to bone fluoride content.

Long-tenn linear NaF effect on young female rat
bone: In the third study, young female Wistar rats were
fed NaF solutions (0-6 mM) with different concentrations ad libitum for three months. The equivalent NaF
dose employed ranged from 0 to 25 mg/kg/d. Although
femoral metaphyseal Cn-BV /TV was shown to increase
with dose, both Cn-OS/BS and Cn-ES/BS were shown
to decrease with dose suggesting NaF toxicity , at least
at the highest dose. Despite reduced bone formation
activity , a positive bone balance was achieved at all
doses and was attributed to more severely reduced bone
resorption activity (Cheng and Bader, 1990b). However, when aged OVX rats (12 months old) were treated
with 10-12 mg/kg/d of NaF for four months, not only
was Cn-BV /TV not increased, but actually decreased
when compared to untreated OVX rats. This adverse
NaF effect on rat bone is probably age-related as this
dose range is slightly toxic only to old rats , as evidenced
by loss of body weight, but not to young rats (Cheng et
al., 1994). In the young rats, NaF builds up bone by
inhibiting bone resorption more than bone formation
(Cheng and Bader, 1990b); but in the old rats, NaF
loses bone by promoting bone resorption more than bone
formation (Cheng et al., 1994).

cantly but decreased the bone quality significantly
(Sogaard et al., 1995).

Possible biphasic NaF effect on adult rat bone:
In the fourth study, 3-month old female rats were treated
with drinking water containing either 5. 3 or 7. 9 mM
NaF for 90 days. Although the lumbar vertebral body
ash weight was significantly increased by each dose, the
vertebral trabecular bone volume was increased significantly only by the lower dose, suggesting possibly NaF
had a biphasic effect in this model. Results from biomechanical testing on the vertebral bodies showed that
NaF at these doses did not affect bone strength signifi-

Lack of favorable NaF effects on ewe bone: In a
short-term (45 days) study on 6-year-old ewes, NaF at
1 or 5 mg/kg/d significantly decreased serum calcium
and phosphorus, and non-significantly decreased iliac
cancellous bone area. Both osteoid surface and eroded
surface were increased significantly. Dynamic parameters showed that single and double labeled surfaces and
adjusted apposition rate were non-significantly decreased
while the mineralization Jag time was significantly
increased (Chavassieux et al. , 1991a).

Biphasic NaF effect on canine bone: We studied
the dose dependence of NaF effects on bone in dogs.
Ovariectomized beagle dams (6-7 year old) were fed
NaF powders in pellets at four levels (0, 1, 3, 5
mg/kg/d) for nine months. Static and dynamic histomorphometric results as observed in ribs and femurs
showed that NaF had a biphasic effect on most bone parameters (Cheng and Bader, 1990a; 1992). Unfortunately, there were only two dogs at each NaF level. _In order to have a meaningful analysis of the data, we have
reanalyzed the data as functions of bone F content. Figure 1 shows that the effect of NaF on proximal femoral
metaphyseal Cn-BV /TV is biphasic (R = 0. 764) with a
maximum at 0.45% bone F content, which is equivalent
to a NaF dose of approximately 2 mg/kg/d. Femoral
cancellous mineral apposition rate (Cn-MAR) behaves
similarly (Figure 2). However, Cn-OV/BV or CnOS/BS, which was significantly elevated by NaF at all
doses, did not show a biphasic pattern. The significant
hyperosteoidosis may be indicative of impaired bone
mineralization.
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FLUORIDE DOG MINERALIZATION PROFILE(Femoral bone)
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Figure 3. Effect of NaF on canine femoral cortical bone mineralization profile as determined by density fractionation.
Dogs were treated with NaF for nine months. Baseline animals were killed at the beginning of the experiment.

Effects of NaF on bone mineral

zation (Grynpas, 1990). FHAP and HAP crystallites
have very similar dimensions, except that FHAP may
have slightly larger cross-sectional areas (Posner et al.,
1963; Grynpas et al., 1986). No change inCa, P, or
Ca/P molar ratio have been reported for fluoridated bone
minerals, but significant changes in Mg, C03 , Na, citrate and ash weight have been reported (Zipkin et al. ,
1960). Since bone quality and bone strength depend on
the bone micro-architecture at the bone mineral level,
the effects of fluoride on the physicochemical properties
of FHAP crystallites are as important as the effects on
bone biology. Firstly, the manner in which the minerals
are formed in the bone matrix , e.g. , packing density,
will affect the bone strength. Secondly, the manner in
which F is incorporated into bone mineral crystallites
may depend on the bone microarchitecture.

Normal bone mineral is poorly crystalline hydroxyapatite [HAP, Ca 10 (P0 4) 6(0HhJ, with dimensions ranging from 10 to 30 nm in length and 5 to 10 nm in thickness. Besides being very small and strained, the crystallites contain many impurities such as C03 , Mg, Na,
etc., some of which have been reported to vary with
fluoride content. Fluoride substitutes for the hydroxyl
ion in apatite to form the thermodynamically more stable, less soluble, albeit still poorly crystalline, fluorhydroxyapatite [FHAP, CaJO(P0 4)6Fx(OH)z_xJ (Eanes and
Reddi 1979; Neuman and Neuman 1958). F ions do
not seem to diffuse into preformed HAP crystallites
which are not near the bone surface, but are incorporated into FHAP crystallites during new bone minerali277
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cal and cancellous bones from rats and dogs and have
found that 19 F NMR results are species independent, but
are dependent on the magnetic field strength and the
bone fluoride concentration. The results suggest that
there are at least two chemically inequivalent F incorporation sites in bone tissue, possibly a surface site and a
bulk site (Code et al., 1990a). In agreement with neutron activation analysis results , 19 F NMR shows that
cortical bone always takes up significantly less F than
cancellous bone. More important, we have observed
that for a given bone F concentration, cortical and cancellous bones do not have the same T 1 values such that
cortical T 1 is significantly shorter than cancellous T 1,
suggesting a stronger fluoride-lattice interaction in cortical bone mineral crystallites. For each bone type, l!T 1
is linearly dependent on bone F content, i.e. , the higher
the bone F content, the shorter the T 1, but the regression
coefficients are different for cortical and cancellous
bones. This also indicates that the local environments of
fluoride in cortical bone and in cancellous bone are not
the same. The longer T 1 in cancellous bone is not related to the higher organic matrix content. It is probably
related to the fact that cancellous bone has a higher percentage of F incorporating surface sites than cortical
bone (Code et al ., 1992). This hypothesis can also explain the shorter T 1 values for more fluoridated bones as
bone F depresses the bone mineral aggregate surface
area (Cheng and Bader, 1990b).

The following two sections seek to relate changes in
fluoridated bone mineral properties to the biphasic effects of NaF on bone as well as to the differential NaF
effects on cortical and cancellous bones.

Effects of NaF on bone mineral packing density and
surface area
Although FHAP and HAP crystallites have similar
dimensions, bone mineral crystallites are packed closer
together in fluoridated rat bone. When fmely ground rat
bone powders were fractionated according to their densities, the percent by weight of powders having a density
greater than 2.1 g/ml was always significantly higher in
fluoridated bone than in control. The F content was also
highest in the same density fraction, indicating that fluoride increased bone mineral packing density (Grynpas et
al., 1986). This finding is supported by the observation
that fluoride reduces bone mineral aggregate surface
area. When rat bones were deproteinized and their bone
mineral aggregate surface areas were studied by nitrogen
adsorptiometry, fluoridated bone showed significantly
lower aggregate surface area per gram of bone than control (Cheng and Bader, 1990b). However, this finding
in rats has not been confirmed in dogs. When canine
femoral cortical bone powders were analyzed by density
fractionation, the results showed that there was a hiphasic NaF effect on bone mineral packing. As can be
seen in Figure 3, which shows the mineralization profiles of untreated and treated canine cortical bones (at
four dose levels), in the density fraction between 2.0 and
2.1 g/ml, there is a peak at the dose of 1 mg/kg/d while
in the density fraction between 2.1 and 2.2 g/rnl, there
is a trough at the same dose. These two density fractions are the more important and sensitive fractions of
the four shown in the figure. Together, they show that
at low dose, NaF promotes hypomineralization (favoring
lower density fractions) and at high dose, it promotes
hypermineralization (favoring higher density fractions).
Since increased mineral packing density could lead to a
more brittle bone, especially for cortical bone, this
adverse NaF effect at high dose could be considered
negative for bone quality.

Conclusions
Unlike the 3-month study on young female rats
which shows a linear dependence of Cn-BV /TV on NaF
dose, the 21-day study on young male rats and the studies on chicks and dogs show biphasic NaF effects on
Cn-OS/BS in chicks and on Cn-BV /TV in dogs and in
young male rats. Biphasic character is also observed in
the effect of NaF on the packing of canine cortical bone
mineral. When taken together, the animal models that
show biphasic NaF effects seem to suggest that NaF at
low dose improves Cn-BV /TV and at high dose undermines it. The results on bone strength and bone quality
are more difficult to assess. At high NaF dose, bone
strength suffers. But no clear verdict can be arrived at
present for the effect on bone strength when low NaF
dose is employed. In humans, high NaF dose does not
help reduce VFR but low dose seems to help. Low NaF
dose (50 mg/d) given in enteric-coated tablets with calcium supplement for 2 years is considered safe (Meunier
and Boivin, 1993). But, even at therapeutic dose, longterm (5 years) NaF treatment may be detrimental to
bone strength and quality , as test results on trabecular
bone from iliac biopsies have shown (Sogaard et al.,
1994).

Fluoride-lattice interactions in bone mineral
Another interesting physical phenomenon of fluoridated bone is the fluoride-lattice interactions in bone
mineral crystallites. This can be measured by 19 F
nuclear magnetic resonance (NMR) in terms of the spinlattice relaxation time (T 1). As with neutron activation
analysis, 19F NMR can be used to measure the bone F
content non-invasively (Code et al., 1990b). We have
studied 19 F nuclear spin-lattice relaxation rates in corti278
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lished that fluoride induces an osteoblastic proliferation
probably through the osteoblast precursors. Besides this
stimulatory effect, fluoride may decrease the osteoblast
activity at the individual cell level. The amplitude of
these effects depends on the total amount of fluoride ingested and may explain the different results in the literature. It will be important to understand the effects of
fluoride in bone cells to completely understand fluoride
effects on bone.
Authors: The effects of fluoride depends on two things:
dose and treatment duration . For a given dose, the
treatment duration counts; and for a given duration, the
dose counts. The effect of fluoride on bone cells is beyond the scope of this review. We do not consider ourselves experienced enough in this area to draw conclusions from the conflicting results published.

Discussion with Reviewers

L. Mosekilde:

How do the authors defme bone
strength? The authors have referred to several papers
where indirect measurement of bone strength has been
performed (e.g., "sonic velocity:); on the other hand,
several papers where direct measurements ofbiomechanical strength of fluoride treated bone have been made
have been omitted or mentioned only very superficially
by the authors.
Authors: Ultimately , bone strength is measured by
bimechanical testing. Indirect measurements should be
of value too, and hence should not be overlooked.

P. Chavassieux: Concerning the effects of fluoride on
bone mineral, all data reported in this paper concern
only animal studies. Is there any human study after
fluoride treatment or in cases of fluorosis?
Authors: Only some early human studies mentioned effects of fluoride on bone mineral, but mostly on their
chemical composition .

L. Mosekilde: Do the authors consider that high-dose
or long-term treatment has a negative effect on "bone
biology" , and on "bone chemistry"?
Authors: High-dose is defmitely the ultimate culprit.
In fluorosis, both bone biology and bone chemistry are
abnormal. As for therapeutic doses, long-term treatment
also has adverse effects on bone strength which we
believe are caused by a change in bone "physical
chemistry" .

L. Mosekilde: What is the relationship in time between
effect on "bone biology" and "bone biochemistry"?
Authors: If NaF dose is high enough to affect bone cell
biology, it will not take long to affect bone biochemistry, e.g., over production of collagen matrix. If the
dose is too low to affect bone cell biology significantly,
only the cumulative F effects on physical chemistry
(crystallography) and material science of bone mineral
will be observed after prolonged exposure.
W.S.S. Jee: Does NaF have any anabolic effects on
periosteal and endocortical surfaces like PTH and PG~?
Authors: To our knowledge, no rat data on cortical
bone is available. NaF has anabolic effects on endocortical surfaces. We are not sure whether it is also true
for periosteal surface.
P. Chavassieux: For a better understanding, it is essential to distinguish the effects of fluoride on bone cells
and on bone mineral, both contributing to the quality of
bone. Concerning the first one, it is now well estab282

